-
EXCLUSIVE: AVEO CEO Explains How New Partnership Will Address $500 Million Opportunity Overseas
Monday, December 21, 2015 - 2:39pm | 828Read More...• AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO) has announced a partnership with EUSA Pharma granting EUSA exclusive European rights to tivozanib. • The deal could reportedly generate nearly $400 million for AVEO. • AVEO CEO Michael Bailey told Benzinga that the tivozanib deal is...
